


OUTLINE


- Methodologies for characterizing the contents of proximal colon

- Characteristics of contents of proximal colon

- Implications for drug absorption

- In vitro simulations for evaluating the impact of luminal characteristics on drug absorption from the proximal colon







BIS for distal colon preparation?

After oral administration BIS is rapidly converted to the active metabolite bis(p-hydroxyphenyl)-2-pyridylmethane (BHPM) and its action is initiated by activating protein kinase C releasing prostaglandin E2 and, thereby, inducing net fluid secretion (in vitro & human data)

Effects on the intralumenal physiology have been shown to be reversible (rat and human data).


Mucus secretion occurs only at BHPM concentrations of at least $1 \mu g/ml$ Sodium and fluid secretion occurs at intracolonic BHPM concentrations of $\ge 5 \mu g/ml$ (rat data)

With the NKUA protocol for colon preparation, after overnight fasting and 5h after a glass of water, BHPM at proximal colon is $\sim 0.5~\mu g/ml$

Also, stools consistency and osmolality of contents at the proximal colon are used as supporting evidence

A useful methodology, especially when considering sensitive populations

Diakidou et al. Pharm. Res 2009



OUTLINE

- Methodologies for characterizing the contents of proximal colon
- Characteristics of contents of proximal colon
- Implications for drug absorption

- In vitro simulations for evaluating the impact of luminal characteristics on drug absorption from the proximal colon





Fluid volumes in the young healthy adult large intestine


Table 1. Gastrointestinal fluid volumes as determined by magnetic resonance imaging (MRI) under fasting conditions and 1 h after a meal (n = 12)


[volumes (mL)]*	[volumes (n	nL] [volumes (mL)
		/
13	45	1
72	319	44
47	83	8
45 (18)	105 (72)	13 (12)
	100000 00 57 Mill.2	
534	20	2
859	156	97
701	39	18
686 (93)	54 (41)	11 (26)
	13 72 47 45 (18) 534 859 701	$\begin{array}{cccccccccccccccccccccccccccccccccccc$


For the fasted large intestine similar values have been reported by Murray et al. (2017)



















Size of non-liqu ultracentrifugation of	•		
	Fasted state	Fed state	
Number of volunteers	5	6	
Volume Mean Diameter	73.60 ± 89.22	262.64 ± 51.64	
(D[4,3], μm) ± SD*			
[*] For each volunteer, 1-4	random samples were m		nas at al 2015
		кер	pas et al. 2015



PChem characteristics of the liquid fraction of contervolution of contervolution of contervolution adults (upper row) – Older adults (65-74y) (lower rows) –				
	Fasted state	Fed state		
	81 (102)	224 (125)		
Osmolality of aqueous fraction (mOsmol/kg)	299 (49)	264 (76)		
Chart Chain Fath, Asida ann antartian in the ann an fault () at	31 (15)	48 (24)		
Short Chain Fatty Acids concentration in the aqueous fraction (mM)	88 (36)	78 (20)		
Lana Chain Fatte Asida ann an thating in the ann ann for this (1984)	120 (83)	225 (201)		
Long Chain Fatty Acids concentration in the aqueous fraction (μ M)	468 (464)	490 (205)		
Chalastaval (UNA)	4756 (6104)	2297 (1969)		
Cholesterol (μM)	1703 (1674)	1882 (1325)		
Dhaanhatid Jahalina (349 (415)	311 (137)		
Phosphatidylcholine (μM)	362 (210)	539 (393)		
In line with the increased buffer capacity in older adults Vertzoni et al. 2020				
Fasted state / UC adults in relapse: SCFAs are signficiantly lower [23.2(14.9)] compared with young healthy Vertzoni et al.				




OUTLINE

- Methodologies for characterizing the contents of proximal colon


- Characteristics of contents of proximal colon


- Implications for drug absorption


- In vitro simulations for evaluating the impact of luminal characteristics on drug absorption from the proximal colon





Characteristics of contents affect drug's availability for transport towards the mucosa			
Why? Potential mechanisms?			
Affect the amounts of drug that are apparently dissolved in the liquid contents and, therefore, available to be transported towards the mucosa	Affect on the capacity of liquid contents to accomodate the drug (apparent solubility) Affect the Release/Dissolution rates May lead to decreased concentrations, due to bacterial degradation of the drug		





















Simulating t	he compositio	on of contents in the lower i	ntestine of you	ng healthy	adults: Fasted sta
-			SIF _{ileum} -V2	FaSSCoF	_
	So	dium cholate (mM)	-	0.15	
		Lecithin (mM)	-	0.3	
	So	odium oleate (mM)	-	0.1	
	1	Maleic acid (mM)	120	75.8	
		Tris (mM)	-	45.4	
		NaOH (mM)	240.6	120	
		рН	8	7.8	
	Buffer capacity [(mmol/L)/ΔpH)]		7.6	14.4	
	Osmolality (mOsmol/kg)		275	217	
-	Level I/II	Volume (mL)	40	200	_
[Liquid volume (mL)	39.9	180.4	1
	Level III	Microcrystalline cellulose (g)	2.18 (250 μm)	31.34	
=					 Georgaka et al. 2017

Simulati	ng the comp	position of contents in the lower in	testine of yo	oung healthy a	adults: Fed s
			SIF _{ileum} -V2	FeSSCoF-V2	
		Sodium cholate (mM)		0.6	
		Lecithin (mM)	-	0.5	
		Sodium oleate (mM)	-	0.2	
		Glucose (mg/ml)	-	4.8	
		Maleic acid (mM)	120	65	
		Tris (mM)	-	65	
		NaOH (mM)	240.6	16.5	
	рН		8	6.0	
	Buffer capacity [(mmol/L)/ΔpH)]		7.6	38	
	Completing (m Compl/kg)		275	170 (Level I)	
	Osmolality (mOsmol/kg)		275	207 (Level II)	
	Level I/II	Volume (mL)	40	200	
	Level III	Liquid volume (mL)	36.1	171.2	
	Leverill	Microcrystalline cellulose 250 µm (g)	6.27	42.00	
				Ge	orgaka et al. 201











18





Based on


- P_{eff} human ileal and colonic permeability values of BCS highly permeable APIs
- Residence times in the regions

Assuming that

- degradation is clinically important when ≥20% reduction in absorption from distal ileum or proximal colon occurs
- degradation and absorption occurs according to 1st order kinetics

30min and 95min seem to be reasonable point estimates of maximum bacterial degradation half-lives, in order bacterial degradation in distal SI and in proximal colon, respectively, to be clinically important

Vertzoni et al. 2018



	•		of bacterial degradation f adults using adult feca	
t _{1/2,SIB} <30min	pounds tested in si bacteria (SCoB). Sin Levodopa Sta Budesonide 20 Nitrendipine		tion half-life (min) of model com- ria (SIB) and in simulated colonic Simulated colonic bacteria (SCoB) Stable ^a 147.0 \pm 7.6 16.7 \pm 1.6 48.7 \pm 2.7	t _{1/2,SCoB} <95min
	Rivaroxaban Str Sulfasalazine a Experiments in not reveal clinically (rivaroxaban) in th	able ³ 3.42 ± 0.45 In SIB or SCoB were not put y important bacterial degrader to comparatively more com-	Stable ^a $\overline{2897 \pm 0.099}$ erformed as these compounds did radation (levodopa) or were stable incentrated bulk fecal material. rature data in humans	



Evaluating the clinical importance of bacterial degradation of therapeutic agents in the lower intestine of adults using adult fecal material


Table 2

Mean (SD) values for the bacterial degradation half-life (min) of model compounds tested in simulated intestinal bacteria (SIB) and in simulated colonic bacteria (SCoB).

	Simulated ileal bacteria (SIB)	Simulated colonic bacteria (SCoB)
Levodopa	Stable ^a	Stable ^a
Budesonide	202.7 ± 2.6	147.0 ± 7.6
Nitrendipine	26.9 ± 3.4	16.7 ± 1.6
Nimodipine	73.2 ± 7.8	48.7 ± 2.7
Rivaroxaban	Stable ^a	Stable ^a
Sulfasalazine	13.42 ± 0.45	7.897 ± 0.090

^a Experiments in SIB or SCoB were not performed as these compounds did not reveal clinically important bacterial degradation (levodopa) or were stable (rivaroxaban) in the comparatively more concentrated bulk fecal material. $\frac{t_{1/2,SIB}}{t_{1/2,SCOB}} \approx \frac{Stool \; content \; in \; SCoB}{Stool \; content \; SIB} \approx 1.5$

i.e. bacterial degradation in SIB could be evaluated from data in SCoB





Acknowledgments

National and Kapodistrian University of Athens M. Vertzoni

A. Diakidou

D. Georgaka

- E. Karatza
- S. Suleiman

Red Cross Hospital, Greece K. Goumas

MSD, USA F. Kesisoglou

University of Copenhagen, Denmark A. Müllertz

Aristotle University of Thessaloniki, Greece D. Fatouros **AZ, Sweden** B. Abrahamsson E. Söderlind

Bayer AG, Germany U. Münster Dorina van der May Elisabeth Kersten



